Exploring how gut bacteria affect cannabis oil treatment in fibromyalgia patients
Official title: Biosignature of the Response to Treatment With Cannabis Oil in Individuals With Fibromyalgia
Run by Rambam Health Care Campus · NCT06946940 · Data updated 2026-11-12
This study is testing how gut bacteria might affect how well cannabis oil works for people with fibromyalgia.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 30 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Rambam Health Care Campus Academic / other |
| Locations | 1 site (Haifa) |
| Status | Recruiting |
| Started | May 30, 2024 |
| Main results expected | May 2026 |
| Study ends | May 2027 |
| Registry record updated | April 27, 2025 |
| Trial ID | NCT06946940 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 30 and over with a confirmed diagnosis of fibromyalgia and significant pain despite standard treatments.
✕Probably not a fit
Patients with recent cannabis use, significant comorbid conditions, or psychiatric disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the relationship between gut microbiome composition and the effectiveness of cannabis oil in treating fibromyalgia. It involves a double-blinded randomized controlled trial with 150 participants who will receive either cannabis oil (5% THC, 5% CBD) or a placebo. The study will assess patient-reported outcomes, sensory testing, and microbiome composition at baseline and during treatment. By analyzing these factors, researchers aim to understand why some patients respond better to cannabis oil than others.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment approaches for fibromyalgia, improving pain management for patients.
How similar studies have gone: While there is growing interest in the use of cannabis for fibromyalgia, this specific approach linking gut microbiome composition to treatment response is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult men and women aged 30 years and over. * Diagnosis of fibromyalgia confirmed according to the 2016 diagnostic criteria by a pain specialist, with relevant symptoms lasting 12 months or more. * An average reported pain ≥ 6 during the preceding week. * Eligible for cannabis at the discretion of the treating physician. * Has remained symptomatic despite receiving standard care for fibromyalgia including analgesics, anti-depressants (tricyclic and SNRI) and anti-epileptic agents. Exclusion Criteria: * Patients who have used cannabis during the preceding month. * Any significant comorbid condition at the discretion of the PI (e.g. inflammatory arthritis, inflammatory bowel disease, cancer). * Personal or family history of psychotic disorders. * Current or past anxiety disorder. * Any uncontrolled psychiatric pathology. * Current or history of substance addiction or abuse. * Diagnosed dementia or cognitive impairment. * Personal history of cardiovascular disease. * Pregnancy, lactation or intention to conceive. * Known allergy to any of the cannabis oil ingredients. * Patients with a history of seizure disorder (excluding childhood febrile convulsions) or epilepsy. * Active liver disease. * Any contraindication to the use of MC. * Inflammatory Bowel Disease (IBD).
Where it's running
-
Rambam Health Care Campus
Haifa, Israel Recruiting
Study contacts
- Principal investigator: Amir Minerbi, MD-PhD — Rambam Health Care Campus
- Study coordinator: May Haddad, PhD
- Email: ma_haddad@rambam.health.gov.il
- Phone: +9724-7772040
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Respiratory Function in Fibromyalgia: A Look at Breath and Muscle Health in Women
This study compares respiratory function, muscle strength, and quality of life between women with fibromyalgia and healthy women to see if fibromyalgia affects breathing and muscle performance.
-
Interoceptive Sensitivity and Central Sensitization in Fibromyalgia
This study tests how people with fibromyalgia perceive internal bodily signals and whether that relates to their symptom burden.
-
Psychologically Informed Physical Therapy (PIPT) for Fibromyalgia delivered online
A small online program tests if a psychologically informed physical therapy approach is feasible, acceptable, and safe for adults with fibromyalgia to help manage symptoms and improve daily functioning.
-
Melatonin and vitamin drip for pain relief in fibromyalgia
This trial tests whether weekly intravenous vitamins plus melatonin can reduce pain and improve quality of life for adults with fibromyalgia compared with a placebo.
-
Remote electrical neuromodulation to test pain inhibition in migraine and fibromyalgia
We’re testing if the Nerivio wearable can boost the body’s natural pain-inhibition system (CPM) and reduce pain more than a sham device in adults with migraine or fibromyalgia.
-
Thickness of the thoracolumbar fascia in women with fibromyalgia
This study tests whether the thoracolumbar fascia is thicker in women with fibromyalgia compared to healthy women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.